ArticleKidney international reports2026
Incorporating Pathomics Into IgAN Risk Prediction.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide, with heterogeneous progression rates. The International IgAN Prediction Tool (IIgAN-PT) enables individualized risk prediction using clinical characteristics and histopathological scoring. However, traditional histopathological scoring is semiquantitative and prone to interobserver variability. Deep learning-based, automated quantification of digitized histopathology enables the extraction of quantitative morphological biomarkers (pathomics). Here, we evaluated the added prognostic value of pathomics over traditional histopathology and its potential integration into the IIgAN-PT. Methods: We analyzed a multicenter European cohort of 555 adults with biopsy-proven IgAN (VALIGA), including centralized histopathology assessment. We assessed the potential of 25 clinically interpretable candidate pathomics predictors across 2 clinically relevant settings by (i) comparing pathomics with traditional histopathology (MEST-C [mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental glomerulosclerosis (S), tubular atrophy and/or interstitial fibrosis (T) and crescents (C)]) and (ii) extending the IIgAN-PT with pathomics. Model performance was evaluated by overall fit, discrimination, reclassification, and calibration. Results: In a direct comparison, pathomics slightly outperformed the MEST-C score when used alone (Δ C-statistic 0.04 (95% confidence interval [CI]: 0.03-0.06)) but was marginally worse after adjusting for clinical predictors (Δ C-statistic -0.034 [95% CI: -0.042 to -0.027]). Patient stratification into clinical risk groups was consistent between models. Combining pathomics and traditional histopathology led to minor improvements over the current IIgAN-PT (without ethnicity, Δ C-statistic 0.024 [95% CI: 0.019-0.028]). Pathomics variables captured chronic morphological changes including glomerular deformation, tubular shrinkage, and arterial luminal narrowing. Conclusion: Our findings indicate that pathomics-derived digital tissue biomarkers provide an additional layer of information and are noninferior to MEST-C, supporting more standardized, robust, and reproducible risk stratification in IgAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.